Safety and Efficacy of Positron Emission Tomography (PET) Imaging With MNI-558
Status:
Completed
Trial end date:
2011-03-01
Target enrollment:
Participant gender:
Summary
This research will look at how the brain may change in people with Alzheimer disease (AD).
The purpose of this research is to find out whether changes in the brain in people with
Alzheimer disease can be detected using a brain imaging test. Most people with Alzheimer
disease have changes in the brain that result in deposits of a protein called beta-amyloid.
In this study, the investigators will be using a radioactive drug, [18F]MNI-558 that binds to
beta-amyloid. This drug is experimental and has not been approved by the FDA. Brain imaging
using PET (positron emission tomography) will be done to see if the investigators can
evaluate the areas of beta-amyloid in the subjects with Alzheimer disease. The investigators
will compare these scans with those done in healthy normal volunteers. PET is a
brain-scanning test used in medicine and scientific research to see how the brain is working.
The PET imaging test used in this study is not being done for diagnostic purposes.